BridgeMD
Long-Term Safety Study of Deucravacitinib versus Ustekinumab in Participants with Psoriasis (PRAGMATYK)
EU CTIS ID: 2023-503766-24-00
What this study is testing
Assess the cardiovascular safety of long-term use of deucravacitinib in comparison to ustekinumab in adults with moderate-to-severe plaque psoriasis
- Phase III and phase IV (Integrated)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Adult participants aged 40 years or older (inclusive)
- Participants with moderate-to-severe plaque psoriasis as defined by a PASI ≥ 12, BSA ≥ 10% and sPGA score ≥ 3 at the time of the Screening Visit and Day 1 visits
- Participants who are candidates for phototherapy or systemic treatment of psoriasis
- Eligible participants should have at least 1 of the following cardiovascular risk factors: Current cigarette smoker, Diagnosis of hypertension or use of blood pressure-lowering medications, Diagnosis of dyslipidemia, Diabetes mellitus type 1 or 2, History of 1 or more of the following CVD events: coronary revascularization procedures including PCI or CABG, MI, cardiac arrest, hospitalization for unstable angina, acute coronary syndrome, stroke, or transient ischemic attack, Obesity defined by a body mass index ≥ 30 kg/m2, Family history of premature coronary heart disease
You likely can't join if
- Recent history of 1 or more of the following cardiovascular events: MI, stroke, history of coronary revascularization, or VTE within 90 days prior to Day 1
- Evidence of active cancer or a history of cancer or lymphoproliferative disease within the previous 5 years
The study team makes the final eligibility decision.
Where it's taking place
- Mexico
- United Kingdom
- Canada
- Brazil
- Japan
- Taiwan
- Chile
- United States
- China
- Australia
- Korea, Republic of
- Argentina
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Mexico; United Kingdom; Canada; Brazil; Japan; Taiwan and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.